Abstract
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is normally expressed in the human immune system and plays a critical role in antitumor immunity. TRAIL interacts with the death receptors, DR4 and DR5, and activates intracellular apoptotic pathway in cancer cells. This discovery has resulted in a rapid development of cancer therapeutic agents that can activate this apoptotic pathway. These therapeutic agents include recombinant human TRAIL (rhTRAIL) and its agonistic monoclonal antibody (MAb) against DR4 and DR5. Phase I trials have established the safety and tolerability of these TRAIL agonists in patients. Phase II trials are currently evaluating the therapeutic efficacy of TRAIL agonists as single agents or in combination with established cancer therapeutics. This review outlines the advances and the challenges in the development of these TRAIL agonists as effective clinical cancer therapeutics.
Keywords: Apoptosis, cancer, death receptor, monoclonal antibody, TRAIL
Reviews on Recent Clinical Trials
Title: TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Volume: 4 Issue: 1
Author(s): Anita C. Bellail, Ling Qi, Patrick Mulligan, Vaninder Chhabra and Chunhai Hao
Affiliation:
Keywords: Apoptosis, cancer, death receptor, monoclonal antibody, TRAIL
Abstract: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is normally expressed in the human immune system and plays a critical role in antitumor immunity. TRAIL interacts with the death receptors, DR4 and DR5, and activates intracellular apoptotic pathway in cancer cells. This discovery has resulted in a rapid development of cancer therapeutic agents that can activate this apoptotic pathway. These therapeutic agents include recombinant human TRAIL (rhTRAIL) and its agonistic monoclonal antibody (MAb) against DR4 and DR5. Phase I trials have established the safety and tolerability of these TRAIL agonists in patients. Phase II trials are currently evaluating the therapeutic efficacy of TRAIL agonists as single agents or in combination with established cancer therapeutics. This review outlines the advances and the challenges in the development of these TRAIL agonists as effective clinical cancer therapeutics.
Export Options
About this article
Cite this article as:
Bellail C. Anita, Qi Ling, Mulligan Patrick, Chhabra Vaninder and Hao Chunhai, TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges, Reviews on Recent Clinical Trials 2009; 4 (1) . https://dx.doi.org/10.2174/157488709787047530
DOI https://dx.doi.org/10.2174/157488709787047530 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Biological Evaluation of Novel 2-imino-4-thiazolidinones as
Potential Antitumor Agents for Glioblastoma
Medicinal Chemistry The Roles of Sox Family Genes in Sarcoma
Current Drug Targets Opportunities for Photoacoustic-Guided Drug Delivery
Current Drug Targets Search for Distinctive Markers in DNT and Cortical Grade II Glioma in Children: Same Clinicopathological and Molecular Entities?
Current Topics in Medicinal Chemistry Exploring a Novel Target Treatment on Breast Cancer: Aloe-emodin Mediated Photodynamic Therapy Induced Cell Apoptosis and Inhibited Cell Metastasis
Anti-Cancer Agents in Medicinal Chemistry Recent Patents, Formulation and Characterization of Nanoliposomes
Recent Patents on Drug Delivery & Formulation Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets Chemoresistance in High-Grade Gliomas: Relevance of Adenosine Signalling in Stem-Like Cells of Glioblastoma Multiforme
Current Drug Targets Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Antiangiogenic Drugs and Tyrosine Kinases
Anti-Cancer Agents in Medicinal Chemistry Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews Realization Methods of Computer-aided Diagnosis System of Medical Images
Recent Patents on Engineering Pro-Oxidant Milieu Blunts Scissors: Insight into Tumor Progression, Drug Resistance, and Novel Druggable Targets
Current Pharmaceutical Design The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry Physiological Functions of Presenilins; Beyond γ-Secretase
Current Pharmaceutical Biotechnology